Despite Beta-blockade therapy has been considered as an absolute contraindication in the treatment of heart failure, it has been shown that they could have a beneficial effect, provided that they were introduced at very low dose, and very progressively in addition of the traditional treatment. The advances in the understanding of the neuro-hormonal mechanisms of heart failure have modified the therapeutic strategy: the deleterious effect of the activation of the sympathetic nervous system on the myocardium has served as the rationale for randomized clinical trials comparing beta- blockade to placebo: the current data are promising, suggesting a beneficial effect on survival as well as on quality of life. However, these results have to be co...
Beta-blockers (β-blockers) are among the recommended group of drugs for the treatment of chronic hea...
Over 5 million Americans are diagnosed with chronic heart failure (CHF) each year. Despite advances ...
Beta-blockers are underutilised in heart failure because clinicians may be unsure whether all beta-b...
For a long time beta-blockers were considered contraindicated for use in heart failure although some...
W hen beta-adrenergic blocking agents were put on thepharmacological market about 40 years ago, thes...
The use of -blockers (BB) in heart failure (HF) has been considered a contradiction for many years. ...
The introduction of blockers of beta-adrenergic receptors (beta-blockers – BB) in the clinical pract...
AbstractDespite recent improvements in the management of congestive heart failure, the prognosis of ...
The use of beta-blocking agents in patients with heart failure is still controversial. An activated ...
Recently, a functional, negatively inotropic, beta(3)-adrenoceptor was characterized in the human he...
Two recent large-scale clinical trials have demon-strated conclusive evidence of the bene®cial effec...
Heart failure is a syndrome in which the heart is unable to supply the entire body with oxygen. It i...
Beta-blocking agents have been shown to reduce the risk of hospitalization and death in patients wit...
Chronic heart failure has been extensively characterized as a disorder arising from a complex intera...
Over 5 million Americans are diagnosed with chronic heart failure (CHF) each year. Despite advances ...
Beta-blockers (β-blockers) are among the recommended group of drugs for the treatment of chronic hea...
Over 5 million Americans are diagnosed with chronic heart failure (CHF) each year. Despite advances ...
Beta-blockers are underutilised in heart failure because clinicians may be unsure whether all beta-b...
For a long time beta-blockers were considered contraindicated for use in heart failure although some...
W hen beta-adrenergic blocking agents were put on thepharmacological market about 40 years ago, thes...
The use of -blockers (BB) in heart failure (HF) has been considered a contradiction for many years. ...
The introduction of blockers of beta-adrenergic receptors (beta-blockers – BB) in the clinical pract...
AbstractDespite recent improvements in the management of congestive heart failure, the prognosis of ...
The use of beta-blocking agents in patients with heart failure is still controversial. An activated ...
Recently, a functional, negatively inotropic, beta(3)-adrenoceptor was characterized in the human he...
Two recent large-scale clinical trials have demon-strated conclusive evidence of the bene®cial effec...
Heart failure is a syndrome in which the heart is unable to supply the entire body with oxygen. It i...
Beta-blocking agents have been shown to reduce the risk of hospitalization and death in patients wit...
Chronic heart failure has been extensively characterized as a disorder arising from a complex intera...
Over 5 million Americans are diagnosed with chronic heart failure (CHF) each year. Despite advances ...
Beta-blockers (β-blockers) are among the recommended group of drugs for the treatment of chronic hea...
Over 5 million Americans are diagnosed with chronic heart failure (CHF) each year. Despite advances ...
Beta-blockers are underutilised in heart failure because clinicians may be unsure whether all beta-b...